Documentation
GlycoMark key studies
- GlycoMark has been used in Japan as a marker for short-term (1 - 2 weeks) glycemic control for the last fifteen years. This utility was confirmed in clinical trials in the United States and GlycoMark has been approved by the FDA for this purpose.
- Dungan K., Buse J. et al. demonstrated the ability of GlycoMark to reflect post-meal glucose excursions in sub-optimally controlled type1 and type 2 diabetic patients. These patients were tested by a continuous glucose monitoring system (CGMS) and also periodic measurements of 1, 5-AG, HbA1c and fructosamine. Their conclusion was that “1,5-AG reflects glycemic excursions, often in the postprandial state, more robustly than A1C of FA. 1,5-AG may be useful as a complementary marker to A1C to assess glycemic control in moderately controlled patients with diabetes.”
- In order to answer the question “Is HbA1c the best measure of glycemic control?,” Dungan K., Buse J. et al. also compared two patients with similar near normal HbA1c levels. The CGMS curve of one of these patients was clearly abnormal with frequent higher postprandial spikes. GlycoMark clearly detected the patient who was not in dietary control. The patient in good control as demonstrated by his CGMS curve had a normal 1, 5-AG level.
- Pharmaceutical manufacturers have used GlycoMark to show the effectiveness of drugs targeting postprandial hyperglycemia, including Januvia, Exenatide and Pramlintide.
- Other studies demonstrating GlycoMark's clinical utility, have been published or are ongoing.
Published papers
- Yamanouchi T et al. 1996. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. The Lancet; 347: 1514 – 1518.
- McGill J et al. 2004. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia. Diabetes Care; 27:8:1859 – 1865.
- Buse J et al. 2006. Serum 1,5-anhydroglucitol (GlycoMarkTM): A short-term glycemic marker. Diabetes Technology & Therapeutics; 5:3:355 – 363.
- Dungan K et al. 2006. 1,5-anhydoglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care; 29;6: 1214 – 1219.
- Dungan, K M. 2008. 1,5-anhydroglucitol (GlycoMarktm) as a marker of short-term glycemic control and glycemic excursions. Expert Rev. Mol. Diagn. 8(1): 9-19.
Abstracts and posters
- Frias J et al. 1,5-Anhydroglucitol (GlycoMark), a PPG excursion marker in pramlintide-treated subjects. American Association of Clinical Endocrinologists 2007 Annual Meeting.
- Button E et al. Comparative Analysis of Three Glycemic Assays - A1C, 1,5-Anhydroglucitol, and Fructosamine.
- Kendall D. et al. Exenatide improves postprandial glucose (PPG) control in patients with type 2 diabetes, as measured by 1,5-anhydroglucitol (GlycoMark). American Diabetes Association 2007 Annual Meeting.
- Akutsu T et al. 1,5-anhydroglucitol and postprandial hyperglycemia as assessed by self-monitoring of blood glucose in Japanese patients with moderately controlled diabetes. American Diabetes Association 2007 Annual Meeting.
- Wittlin S et al. The Use Of 1,5-Anhydroglucitol (Glycomark) To Monitor New Classes Of Therapies For Managing Postmeal Glucose In Patients With Diabetes
Downloadable files
- Clinical studies reveal underlying treatment effects. [4.5MB PowerPoint]
- Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia.
- 1,5-anhydoglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.
- 1,5-anhydroglucitol (GlycoMarktm) as a marker of short-term glycemic control and glycemic excursions.
- Reagent package insert
- Controls package insert
- Standard package insert
